Calamos Advisors LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,387 shares of the medical research company’s stock after buying an additional 30 shares during the period. Calamos Advisors LLC’s holdings in Amgen were worth $14,513,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Oak Associates Ltd. OH raised its position in Amgen by 0.3% in the first quarter. Oak Associates Ltd. OH now owns 210,710 shares of the medical research company’s stock worth $31,592,000 after buying an additional 581 shares in the last quarter. PGGM Investments raised its position in Amgen by 9.7% in the second quarter. PGGM Investments now owns 725,684 shares of the medical research company’s stock worth $110,413,000 after buying an additional 64,011 shares in the last quarter. National Pension Service raised its position in Amgen by 4.2% in the first quarter. National Pension Service now owns 378,322 shares of the medical research company’s stock worth $56,722,000 after buying an additional 15,376 shares in the last quarter. Geode Capital Management LLC raised its position in Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock worth $964,334,000 after buying an additional 132,632 shares in the last quarter. Finally, Prudential PLC raised its position in Amgen by 41.4% in the first quarter. Prudential PLC now owns 1,062,893 shares of the medical research company’s stock worth $159,359,000 after buying an additional 311,157 shares in the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.36% during mid-day trading on Friday, reaching $167.50. The company had a trading volume of 1,679,823 shares. The firm has a 50 day moving average of $170.75 and a 200-day moving average of $161.82. The stock has a market capitalization of $125.35 billion, a P/E ratio of 17.14 and a beta of 0.94. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.57 earnings per share. Analysts forecast that Amgen Inc. will post $11.35 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.39%. The ex-dividend date was Monday, August 15th. Amgen’s dividend payout ratio is currently 40.90%.
Several brokerages have issued reports on AMGN. BMO Capital Markets reissued a “buy” rating and issued a $186.00 price target on shares of Amgen in a research note on Tuesday, July 12th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $165.78 price target on the stock in a research note on Wednesday, July 27th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $206.00 price target (up from $204.00) on shares of Amgen in a research note on Tuesday, September 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.